Form D · Pharmaceuticals

Context Therapeutics Inc.

Philadelphia, PA · CIK 0001842952

Offering snapshot reported May 16, 2024 · SEC filing

Reported sold
$100M
Offering amount: $100M
Investors reported
26
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 6, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 16, 2024Initial$99,992,767No comparison26SEC filing

Offering details

Securities
Equity, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$5M
Finders' fees
$0
Form D file number
021-513547
Includes sale of (i) 59,032,259 shares of common stock ("Common Stock") at $1.55 per share &(ii) pre-funded warrants to purchase 5,482,741 shares of Common Stock, at exercise price of $0.001 per share, with $1.549 per share paid by each warrant purchaser.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Piper Sandler & Co.665

Source: Form D, filed May 16, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Richard Jay Berman Director
Jennifer Evans Stacey Director
Philip Kantoff Director
Martin Albert Lehr Director, Executive
Alex Levit Executive
Jennifer Minai Azary Executive
Linda Beth West Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
2001 Market Street Suite 3915 Unit #15
Philadelphia, PA, 19103